“Goddess of medicine” Glenn has become the top stream of 100 billion.
On January 22, China Europe Fund disclosed the 2021 fourth quarter report of some of its funds. According to the latest data of , by the end of 2021, the scale of the five funds managed by star fund manager Ge Lan officially exceeded 100 billion yuan, reaching 110.339 billion yuan, an increase of 13.338 billion yuan compared with 97.001 billion yuan at the end of the third quarter of 2021.
Among them, the scale of medical and health care in China and Europe at the helm of Glenn increased the most, an increase of 14.065 billion yuan over the end of the third quarter, an increase of 22.17% month on month.
Although in 2021, there was a significant pullback in China EU health care, with an overall return of – 6.55%, investors did not leave the market, but increased their positions against the trend. At present, the scale under Ge Lan’s management has exceeded that of Zhang Kun, the top flow fund manager of e fund, and the scale ranks first in the Equity Fund temporarily.
investors add positions against the market
Pharmaceutical stocks were the absolute focus of the A-share market, especially after the outbreak of covid-19 epidemic in 2020.
A number of big pharmaceutical stocks such as Wuxi Apptec Co.Ltd(603259) , Jiangsu Hengrui Medicine Co.Ltd(600276) have been born in the market, and many pharmaceutical theme fund managers have also been achieved. Ge Lan of China Europe Fund is recognized as the “first sister” of pharmaceutical theme fund.
According to public data, Glenn studied in the Department of Engineering Physics of Tsinghua University, and then obtained a doctorate in biomedical engineering from Northwestern University.
Since 2011, Glenn has been a researcher in Sinolink Securities Co.Ltd(600109) and Minsheng Canada Bank fund, covering industries such as power equipment, new energy and medicine. His team has won the first place in new wealth.
In October 2014, Ge Lan joined the China Europe Fund and successively served as a researcher, China Europe Mingrui new starting point, China Europe Jinquan flexible configuration, China Europe Jinyuan flexible configuration, China Europe Jin and flexible configuration fund manager.
At present, Glenn manages five funds, namely, China Europe medical and health, China Europe Mingrui new starting point, China Europe alpha, China Europe medical innovation and China Europe research selected funds.
In June 2021, Ge Lan’s representative work, the net value of China EU medical and health, reached the peak, achieved a good result of 350% growth in four years, and was sought after by a large number of investors.
However, in the second half of 2021, with the adjustment of the pharmaceutical industry, the fund performed poorly, and the net value retreated by more than 30%.
However, investors did not choose to leave, but increased their positions against the trend. The scale of China EU medical and health fund at the end of the fourth quarter of 2021 was 77.505 billion yuan, an increase of 14.065 billion yuan compared with 63.44 billion yuan at the end of the third quarter.
In addition, the scale of China Europe medical innovation, another pharmaceutical theme fund managed by Glenn, increased slightly at the end of the fourth quarter of 2021, an increase of 1.476 billion yuan compared with the end of the third quarter.
The overall size of the other three funds managed by Glenn declined slightly. Among them, at the end of the fourth quarter of 2021, China EU alpha shrank by 1.6 billion yuan compared with the third quarter, China EU Mingrui’s new starting point shrank by 300 million yuan, and China EU research selection shrank by 300 million yuan
continued to increase the position of pharmaceutical, and the overall position decreased
In the fourth quarter of 2021, Glenn’s position changed.
In the fourth quarter of 2021, the overall stock position of China EU medical and health fund, which has the largest growth, decreased to 81.47%, down 8.15%. Among the other two 10 billion funds, the stock position of China EU medical innovation increased slightly, floating 0.98%.
On the other hand, in terms of heavy stocks, China EU medical and health further increased its position in the pharmaceutical sector in the fourth quarter.
Among the top ten heavyweight stocks, Wuxi Apptec Co.Ltd(603259) is still the largest heavyweight stock, with the latest market value of 9.642 billion yuan, an increase of 1.309 billion yuan compared with the third quarterly report of 2021. Newly held Wuxi Apptec Co.Ltd(603259) 81.31 million shares, an increase of 49% over 54.53 million shares in the third quarterly report of 2021. In addition, Aier Eye Hospital Group Co.Ltd(300015) , Asymchem Laboratories (Tianjin) Co.Ltd(002821) , Hangzhou Tigermed Consulting Co.Ltd(300347) , Pharmaron Beijing Co.Ltd(300759) , Topchoice Medical Co.Inc(600763) have increased positions to varying degrees.
Newly entering the top ten heavyweight stocks are Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) , Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) , and exiting the top ten are Chongqing Zhifei Biological Products Co.Ltd(300122) and Shanghai Medicilon Inc(688202) . The larger change in position is Aier Eye Hospital Group Co.Ltd(300015) , with the number of shares increased from about 109 million shares at the end of the third quarter of last year to about 141 million shares at the end of the fourth quarter.
For the operation ideas, Glenn said in the four seasons that it has generally maintained the operation of high positions and has focused on the long-term promising innovative drug industry chain, medical services and leading enterprises of high-quality generic drugs.
from the perspective of future configuration direction, Gran pointed out that the innovative drug industry chain is still her most promising direction for a long time. from the top-level design of policies at the national level to the innovation accumulation of Chinese enterprises in recent years, China’s innovative pharmaceutical industry chain has been maintained in a high-profile state for a long time.
In addition, with the improvement of Chinese residents’ consumption ability, knowledge structure and cognitive level, the penetration of products and services and the residents’ ability to pay are continuously improving, and the leading enterprises in relevant industries also have long-term growth space.
